Shares of UCB S A/ADR (OTCMKTS:UCBJY) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $38.56 and traded as high as $40.00. UCB S A/ADR shares last traded at $40.00, with a volume of 463 shares traded.
Separately, Goldman Sachs Group upgraded shares of UCB S A/ADR from a “neutral” rating to a “buy” rating in a research report on Thursday, May 30th.
UCB S A/ADR Company Profile (OTCMKTS:UCBJY)
UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company's core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.
Featured Story: Sell-Side Analysts
Receive News & Ratings for UCB S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.